Storm Therapeutics closed a $56 million Series C financing to support Phase II development of STC-15, an RNA modification targeting program in sarcoma. The company said it has already treated the first patient in the trial and expects Phase 2 results across multiple sarcoma indications. STC-15 is designed to inhibit METTL3, an enzyme involved in mRNA methylation, with a Phase I program reporting durable tumor regression across sarcoma subtypes. The company framed the approach around sarcoma biology where malignant survival can depend on METTL3-driven methylation. The financing underscores continued investor focus on RNA-targeting oncology strategies and the push to translate early responses into broader clinical evidence for accelerated pathways.